Navigation Links
Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
Date:7/22/2009

al, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will not receive some or all of the future milestone payments or royalties, the risk that the program does not have significant upside potential and the risk that sales of anti-VEGF antibodies do not achieve the levels projected by some market analysts. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release

    Contacts:

    Peregrine Pharmaceuticals Inc
    Investors                          
'/>"/>
SOURCE  Peregrine Pharmaceuticals, Inc.; Affitech A/S
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)...at the National Institute of Standards and Technol...nexpensive method for detecting and measuring elus...s, invisible spoilage in food or pesticides distri...od is more sensitive than conventional techniques ... polarlike water molecules, having distinct electr...
(Date:11/18/2009)...RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ -...nced today that data from the University of Pennsy... of Sangamo,s zinc finger nuclease (ZFN) based pro...d prematurely disclosed on the internet. ,, Dat...sity of Pennsylvania School of Medicine from a sin...
(Date:11/18/2009)..., NEW YORK, Nov. 18 Reportlinker...s available in its catalogue. ,, Biotechnolog... http://www.reportlinker.com/p0164375/Biotechnolog...source=prnewswire&utm_medium=pr&utm_campai...gy are complex chemical compounds used in a range ...
(Date:11/18/2009)...VT-111 significantly reduces key cardiac enzymes a... presented at American Heart Association 2009 Scie...wire/ - Viron Therapeutics Inc., a biotechnology c...ting protein therapeutics derived from pathogens, ...rial evaluating VT-111 (Serp-1), an anti-inflammat...
Breaking Biology Technology:Prototype NIST method detects and measures elusive hazards 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 2Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 3Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 4Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 5Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 6Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 7Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 8Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 4
...looking for an ambitious mission statement, consid...l Finance Adequacy Initiative: "We will not simply...ars, but propose a complete new reuse of all dolla...ol) system, and then any additional dollars if tha...om Still is a member of the initiative] , ,In oth...
... Wis. The Eau Claire Area Economic Development ...rting up again, offering cash awards of up to $10,...nty. , ,For interested entrepreneurs, the EDC is h...en entrants in the Creating Your Own Business Con...ications. , ,Businesses judged to have the best pl...
...now you,ve had a chance to absorb all the news fro...ators, stage presentations here -- click on DEMO... a company). , ,One question that always swirls ar...t want to know what wasn,t at DEMO. The premise of...at hundreds of products and companies and bring on...
Other Biology Technology:Measuring what works and what doesn't in the prototypical school 2Measuring what works and what doesn't in the prototypical school 3Why companies don't get invited to the DEMO conference 2Why companies don't get invited to the DEMO conference 3
(Date:11/21/2009)...ed, Germany, November 20,2009 / b3c newswire / -...tion of a financing round, gaining two new investo...he same time KINAXO reports that Jrgen Schumacher ...dvisory board. , KINAXO shareholders Axel Ullric... companys institutional investors Mountain Partner...
(Date:11/20/2009)...researchers are at work on many scientific and tec...ion has recently provided support that totals near...lowing investigators under the American Recovery a...s have been awarded grants for investigation of so...essor of physics, will enhance the capabilities of...
(Date:11/20/2009)...search report published in the November 2009 issue...rg ), scientists show how a family of genes (1-ami...s) are responsible for production of ethylene. Thi...nd this information lays the foundation for future...se resistant, able to survive and thrive in diffic...
Breaking Biology News(10 mins):KINAXO Completes Financing Round to Enhance Biomarker Development 2KINAXO Completes Financing Round to Enhance Biomarker Development 3NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2It's a gas: New discovery may lead to heartier, high-yielding plants 2Cleveland Lawyers Recognized by Peers on The Best Lawyers in America List 57298 1Cleveland Lawyers Recognized by Peers on The Best Lawyers in America List 57298 2Cleveland Lawyers Recognized by Peers on The Best Lawyers in America List 57298 3Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 14069 1Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 14069 2ISSA Recognized as Military Friendly School 57294 1ISSA Recognized as Military Friendly School 57294 2
...N, Va., Nov. 18 Stanley, Inc.,(NYSE: SXE ), a l...ional,services to the U.S. federal government, tod...ence Applications International Corporation (NYSE:...task order valued at up to $37.9 million, if,all t...the team will continue,to provide in-service engin...
...BRUNSWICK, N.J. Families gathering around the Tha... side dish that,s been given some "upscale" breedi...he age-old staple will look or taste no different ...elping growers increase production and improve fru...elping them meet the increasing year-round demand ...
...ork, NY, November 18, 2008 -- Researchers at the U...ed that two common cancer drugs have been used to ...F-funded study, published in The Proceedings of t...ey Bluestone, Ph.D., director of the Diabetes Cent...ity. , "The findings suggest that kinase inhibito...
Other Biology News:Stanley to Continue Biometrics In-Service Engineering Support for U.S. Army 2Stanley to Continue Biometrics In-Service Engineering Support for U.S. Army 3Favorite Thanksgiving dish gets 'upscale' breeding 2
Chaperone Sampler Kit from BD Biosciences Pharmingen
Zonula Adherens Sampler Kit from BD Biosciences Pharmingen
Tumor Suppressor Sampler Kit from BD Biosciences Pharmingen
UCB Eosinophil Chip-IHC from 3H Biomedical AB
Biology Products: